Biotech M&A Anomalies With Allan Shaw
Business Of Biotech
00:00
Oncology
I think if you peel the onion on that, you'll see that from an industry perspective, the capital allocation is is overly redundant. Do we need 20 PDL ones? Do we need everybody hitting all these different targets? They're doing the same thing. If the industry tried to rationalize the resources that we have collectively, we can we can stop some of the redundant efforts that are only cannibalizing that science as well. Well, he's welcome on the show anytime, anytime. Are you a star now, Boo Boo? Yeah, the star. All right. One more I'm gonna hit you with one more and then I'm gonna let you I need you got a you got
Transcript
Play full episode
